Clinical Trial Update: A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial comparing upadacitinib to placebo in adults with rheumatoid arthritis who are on csDMARDs and have inadequate response to csDMARDs; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-10-21